Skip to main content

Liquid biopsy, cfDNA, and ctDNA: new technologies and clinical applications

This series intends to collect studies on latest developments in new technologies and clinical applications on liquid biopsy, cfDNA, and ctDNA. Discovery and validation of new biomarkers for diagnosis, therapy and prognosis for human diseases are welcome also.

Radiogenomic biomarkers

For this collection, guest edited by Dr. Jeon-Hor Chen (University of California, Irvine), we cordially invite manuscripts from different disciplines. High quality manuscripts related to disease diagnosis, prediction of treatment response, and assessment of disease risk and outcome are encouraged. Manuscripts outside of these topics which are within the scope of translational research are also welcome.

CAHON: Stop hate crimes and racism

The Chinese American Hematologist and Oncologist Network (CAHON) has published an important and timely Editorial in the Journal of Hematology & Oncology. We are proud to stand with them in denouncing in the strongest terms all forms of discrimination and crimes against any racial/ethnic group, including Asian Americans and Pacific Islanders, and to call on our readers to pursue racial equality and tolerance in the USA and beyond. 

Articles

  1. Authors: Anna Citarella, Zein Mersini Besharat, Sofia Trocchianesi, Tanja Milena Autilio, Antonella Verrienti, Giuseppina Catanzaro, Elena Splendiani, Zaira Spinello, Silvia Cantara, Patrizia Zavattari, Eleonora Loi, Cristina Romei, Raffaele Ciampi, Luciano Pezzullo, Maria Grazia Castagna, Antonio Angeloni…

Editors-in-Chief

Chung-Tsen Hsueh, Loma Linda University
Delong Liu, New York Medical College

Aims and scope

Biomarker Research is an open access, peer-reviewed journal that encompasses all aspects of biomarker investigation. Biomarker Research aims to publish original discoveries, novel concepts, commentaries and reviews related to biomarker investigation from all biomedical disciplines. Read more.

Announcing the launch of In Review

Biomarker Research, in partnership with Research Square, is now offering In Review. Authors choosing this free optional service will be able to:

  • Share their work with fellow researchers to read, comment on, and cite even before publication
  • Showcase their work to funders and others with a citable DOI while it is still under review
  • Track their manuscript - including seeing when reviewers are invited, and when reports are received 

Springer Nature Oncology Portfolio

Discover the range of academic oncology titles at Springer Nature here.

Annual Journal Metrics

  • 2022 Citation Impact
    11.1 - 2-year Impact Factor
    9.6 - 5-year Impact Factor
    1.808 - SNIP (Source Normalized Impact per Paper)
    2.379 - SJR (SCImago Journal Rank)

    2022 Speed
    5 days submission to first editorial decision for all manuscripts (Median)
    76 days submission to accept (Median)

    2022 Usage
    823,359 downloads
    635 Altmetric mentions